Inhibition of Ovarian Cancer by RGD-P125A-endostatin-Fc Fusion Proteins

Overview

Journal Int J Cancer

Specialty Oncology

Date 2011 Jan 13

PMID 21225621

Citations 6

Authors

Yawu Jing

Huarui Lu

Kailang Wu

Indira V Subramanian

S Ramakrishnan

Affiliations

Soon will be listed here.

Abstract

Previous studies have shown that a single point mutation in endostatin at position 125 (P125A) can improve the biological activity of endostatin. Addition of an integrin-targeting moiety, R-G-D, resulted in better localization to tumor vasculature and improved the antiangiogenic activity of endostatin. Because endostatin has relatively shorter serum half-life, frequent dosing was required for inhibiting tumor growth. In our study, we have genetically fused RGD-P125A-endostatin to Fc of IgG4 isotype and evaluated its antiangiogenic and antitumor effects in athymic mice. Two genetic constructs were made, RGD-P125A-endostatin-Fc (RE-Fc) and P125A-endostatin-RGD-Fc (ER-Fc). Both constructs were cloned and expressed in mammalian cells. Purified fusion proteins inhibited endothelial cell migration and proliferation better than yeast-derived P125A-endostatin. Both RE-Fc and ER-Fc inhibited ovarian cancer growth and were found to be as effective as Bevacizumab treatment. Fusion protein showed marked increased half-life. Combination treatment with Bevacizumab and ER-Fc showed additive inhibition of ovarian cancer growth. These studies demonstrate that genetic fusion with human IgG4-Fc increases the half-life of P125A-endostatin and can be used along with Bevacizumab to improve antiangiogenic and antitumor activities.

Citing Articles

Anti-angiogenic therapy in ovarian cancer: Current understandings and prospects of precision medicine.

Mei C, Gong W, Wang X, Lv Y, Zhang Y, Wu S Front Pharmacol. 2023; 14:1147717.

PMID: 36959862 PMC: 10027942. DOI: 10.3389/fphar.2023.1147717.

PEP06 polypeptide 30 exerts antitumour effect in colorectal carcinoma via inhibiting epithelial-mesenchymal transition.

Yu S, Li L, Tian W, Nie D, Mu W, Qiu F Br J Pharmacol. 2018; 175(15):3111-3130.

PMID: 29722931 PMC: 6031886. DOI: 10.1111/bph.14352.

The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering.

Mohajeri A, Sanaei S, Kiafar F, Fattahi A, Khalili M, Zarghami N Adv Pharm Bull. 2017; 7(1):21-34.

PMID: 28507934 PMC: 5426730. DOI: 10.15171/apb.2017.004.

Matricryptins Network with Matricellular Receptors at the Surface of Endothelial and Tumor Cells.

Ricard-Blum S, Vallet S Front Pharmacol. 2016; 7:11.

PMID: 26869928 PMC: 4740388. DOI: 10.3389/fphar.2016.00011.

Inhibition of epithelial ovarian cancer by Minnelide, a water-soluble pro-drug.

Rivard C, Geller M, Schnettler E, Saluja M, Vogel R, Saluja A Gynecol Oncol. 2014; 135(2):318-24.

PMID: 25172764 PMC: 4582668. DOI: 10.1016/j.ygyno.2014.08.031.

References

Kontermann R . Strategies to extend plasma half-lives of recombinant antibodies. BioDrugs. 2009; 23(2):93-109. DOI: 10.2165/00063030-200923020-00003. View

Yokoyama Y, Ramakrishnan S . Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int J Cancer. 2004; 111(6):839-48. DOI: 10.1002/ijc.20336. View

Liu B, Soloviev I, Chang P, Lee J, Huang X, Zhong C . Stromal cell-derived factor-1/CXCL12 contributes to MMTV-Wnt1 tumor growth involving Gr1+CD11b+ cells. PLoS One. 2010; 5(1):e8611. PMC: 2801592. DOI: 10.1371/journal.pone.0008611. View

Wild R, Ramakrishnan S, Sedgewick J, Griffioen A . Quantitative assessment of angiogenesis and tumor vessel architecture by computer-assisted digital image analysis: effects of VEGF-toxin conjugate on tumor microvessel density. Microvasc Res. 2000; 59(3):368-76. DOI: 10.1006/mvre.1999.2233. View

Chung A, Lee J, Ferrara N . Targeting the tumour vasculature: insights from physiological angiogenesis. Nat Rev Cancer. 2010; 10(7):505-14. DOI: 10.1038/nrc2868. View

Lo K, Sudo Y, Chen J, Li Y, Lan Y, Kong S . High level expression and secretion of Fc-X fusion proteins in mammalian cells. Protein Eng. 1998; 11(6):495-500. DOI: 10.1093/protein/11.6.495. View

Capon D, Chamow S, Mordenti J, Marsters S, Gregory T, Mitsuya H . Designing CD4 immunoadhesins for AIDS therapy. Nature. 1989; 337(6207):525-31. DOI: 10.1038/337525a0. View

Markman M, Markman J, Webster K, Zanotti K, Kulp B, Peterson G . Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: implications for patient management and clinical trial design. J Clin Oncol. 2004; 22(15):3120-5. DOI: 10.1200/JCO.2004.05.195. View

Crawford Y, Kasman I, Yu L, Zhong C, Wu X, Modrusan Z . PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell. 2008; 15(1):21-34. DOI: 10.1016/j.ccr.2008.12.004. View

10.

Subramanian I, Nguyen T, Truskinovsky A, Tolar J, Blazar B, Ramakrishnan S . Adeno-associated virus-mediated delivery of a mutant endostatin in combination with carboplatin treatment inhibits orthotopic growth of ovarian cancer and improves long-term survival. Cancer Res. 2006; 66(8):4319-28. DOI: 10.1158/0008-5472.CAN-05-3297. View

11.

Lakatosova-Andelova M, Duskova M, Lucansky V, Paral P, Vonka V . Effects of endostatin production on oncogenicity and metastatic activity of HPV16-transformed mouse cells: role of interleukin 1alpha. Int J Oncol. 2009; 35(1):213-22. DOI: 10.3892/ijo_00000331. View

12.

Folkman J . Antiangiogenesis in cancer therapy--endostatin and its mechanisms of action. Exp Cell Res. 2005; 312(5):594-607. DOI: 10.1016/j.yexcr.2005.11.015. View

13.

Ozols R . Gynecologic Oncology Group (GOG-USA) trials in ovarian cancer. Adv Exp Med Biol. 2008; 622:131-43. DOI: 10.1007/978-0-387-68969-2_11. View

14.

Bookman M, Brady M, McGuire W, Harper P, Alberts D, Friedlander M . Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009; 27(9):1419-25. PMC: 2668552. DOI: 10.1200/JCO.2008.19.1684. View

15.

OReilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W . Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997; 88(2):277-85. DOI: 10.1016/s0092-8674(00)81848-6. View

16.

Shojaei F, Wu X, Malik A, Zhong C, Baldwin M, Schanz S . Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat Biotechnol. 2007; 25(8):911-20. DOI: 10.1038/nbt1323. View

17.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

18.

Ferrara N . Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev. 2009; 21(1):21-6. DOI: 10.1016/j.cytogfr.2009.11.003. View

19.

Kandalaft L, Motz G, Busch J, Coukos G . Angiogenesis and the tumor vasculature as antitumor immune modulators: the role of vascular endothelial growth factor and endothelin. Curr Top Microbiol Immunol. 2010; 344:129-48. DOI: 10.1007/82_2010_95. View

20.

Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D . Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2011; 127(12):2893-917. DOI: 10.1002/ijc.25516. View